# Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

> **NCT00636545** · PHASE1 · COMPLETED · sponsor: **Genta Incorporated** · enrollment: 25 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Oblimersen (Genasense)
- **DRUG:** Oblimersen (Genasense)

## Key facts

- **NCT ID:** NCT00636545
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-03
- **Final completion:** 2010-03
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2012-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00636545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00636545, "Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00636545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*